GlassScriptPhysician profile
Andrew Gerry
NPI 1114232576
$7,369.63
in general payments reported to CMS, 2019-2025
42 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $906 · 2023: $1,432 · 2024: $2,026 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,548.16 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,712.51 | 2021-2025 | |
| Pfizer INC. | $1,301.18 | 2021-2025 | |
| Novo Nordisk INC | $510.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $439.20 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $350.81 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $345.94 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $331.85 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| E.R. Squibb & Sons, L.L.C. | $226.77 | 2021-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $224.13 | 2023-2025 | Veozah, Xtandi |
| Abbott Laboratories | $179.85 | 2024-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $160.55 | 2022-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $160.46 | 2023-2025 | |
| Exact Sciences Corporation | $157.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $146.93 | 2021-2023 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $138.88 | 2024-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gerry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.